RecruitingNCT03932279
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Sponsor
Northwestern University
Enrollment
300 participants
Start Date
Jan 30, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
Eligibility
Min Age: 18 YearsMax Age: 89 Years
Plain Language Summary
Simplified for easier understanding
This study is collecting skin swabs and blood samples from people with cutaneous T-cell lymphoma (a rare skin cancer), psoriasis, eczema, or healthy skin, to understand how the bacteria living on the skin differ between these groups.
**You may be eligible if...**
- You are between 18 and 89 years old
- You have cutaneous T-cell lymphoma (any stage), a CD30+ lymphoproliferative skin disorder, plaque psoriasis, moderate-to-severe atopic dermatitis (eczema), or you are a healthy volunteer
- You are willing and able to provide informed consent
**You may NOT be eligible if...**
- You are outside the age range of 18-89
- You are unable or unwilling to provide consent
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03932279
Related Trials
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
NCT070554771 location
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
NCT059560411 location
Photopheresis in Early-stage Mycosis Fungoides
NCT056805581 location
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
NCT073562451 location
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
NCT066988221 location